PubRank

Saye H Khoo

Author PubWeight™ 57.05‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008 2.52
2 Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother 2005 1.57
3 HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010 1.57
4 Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Antivir Ther 2011 1.53
5 Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet Genomics 2012 1.50
6 Open source clinical science for emerging infections. Lancet Infect Dis 2014 1.47
7 Will ART rollout in Africa drive an epidemic of drug resistant HIV? AIDS 2006 1.42
8 Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther 2011 1.33
9 Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther 2005 1.28
10 Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 2005 1.20
11 Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England. BMJ Open 2013 1.12
12 Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit 2004 1.12
13 Pharmacogenetics of HIV therapy. Pharmacogenet Genomics 2006 1.11
14 Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2010 1.11
15 Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob Agents Chemother 2006 1.10
16 Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2007 1.04
17 Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis (Edinb) 2007 1.04
18 Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort. PLoS One 2011 0.98
19 The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses 2004 0.98
20 P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antivir Ther 2009 0.98
21 Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2010 0.98
22 Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2009 0.98
23 Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antivir Ther 2004 0.98
24 Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin Infect Dis 2013 0.97
25 Intracellular pharmacokinetics of antiretroviral agents. J HIV Ther 2004 0.94
26 Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis 2014 0.94
27 Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. AIDS 2002 0.90
28 Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings. J Clin Microbiol 2012 0.89
29 In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J Pharmacol Exp Ther 2005 0.89
30 Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2002 0.89
31 Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. J Antimicrob Chemother 2008 0.88
32 Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol 2004 0.88
33 Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. Adv Healthc Mater 2013 0.87
34 Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Antivir Ther 2004 0.87
35 Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. J Antimicrob Chemother 2008 0.87
36 Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antivir Ther 2012 0.85
37 Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antivir Ther 2003 0.85
38 Kidney transplantation in HIV-positive adults: the UK experience. Int J STD AIDS 2013 0.84
39 Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. Antimicrob Agents Chemother 2013 0.83
40 Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother 2012 0.83
41 Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance. AIDS 2005 0.83
42 Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2003 0.82
43 Pharmacogenetics of antiretroviral agents. Curr Opin HIV AIDS 2008 0.81
44 Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting. J Antimicrob Chemother 2012 0.80
45 Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. Ther Drug Monit 2008 0.80
46 Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry. Bioanalysis 2014 0.79
47 Effect of transporter modulation on the emergence of nelfinavir resistance in vitro. Antivir Ther 2007 0.79
48 The role of clinical pharmacology in optimizing antiretroviral therapy. Br J Clin Pharmacol 2003 0.79
49 Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. AIDS 2013 0.79
50 Interactions of tenofovir, Lamivudine, abacavir and Didanosine in primary human cells. Pharmaceutics 2011 0.78
51 Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. J Antimicrob Chemother 2007 0.78
52 Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. J Antimicrob Chemother 2007 0.77
53 Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'. AIDS 2007 0.77
54 Abacavir forms novel cross-linking abacavir protein adducts in patients. Chem Res Toxicol 2014 0.76
55 No room for complacency on drug resistance in Africa. Nature 2006 0.76
56 Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2010 0.76
57 Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 2006 0.75
58 Treating advanced HIV infection. J Acquir Immune Defic Syndr 2003 0.75
59 Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer. J Chromatogr B Analyt Technol Biomed Life Sci 2013 0.75